SPTX (Seaport Therapeutics) Current Deferred Taxes Liabilities: $0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SPTX Seaport Therapeutics Inc SPTX
11 GF Score
Price $24.04
! 2 Warning Signs
View Full Analysis

What is Seaport Therapeutics Current Deferred Taxes Liabilities?

Seaport Therapeutics SPTX -0.99% 11 Current Deferred Taxes Liabilities is $0.00 Mil as of Dec. 2025. GuruFocus rates SPTX with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Seaport Therapeutics's current deferred tax liabilities for the quarter that ended in Dec. 2025 was $0.00 Mil.

Seaport Therapeutics Current Deferred Taxes Liabilities Related Terms

Seaport Therapeutics Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for Seaport Therapeutics's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seaport Therapeutics Current Deferred Taxes Liabilities Chart

Seaport Therapeutics Annual Data
Trend Dec24 Dec25
Current Deferred Taxes Liabilities
0.00 0.00

Seaport Therapeutics Semi-Annual Data
Dec24 Dec25
Current Deferred Taxes Liabilities 0.00 0.00
SPTX
11GF Score
Seaport Therapeutics Inc SPTX
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of $0.00 Mil mean?
Seaport Therapeutics (SPTX) has a Current Deferred Taxes Liabilities of $0.00 Mil as of Dec. 2025. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Seaport Therapeutics and its competitors.
Is Seaport Therapeutics' Current Deferred Taxes Liabilities too high?
Seaport Therapeutics' current Current Deferred Taxes Liabilities is $0.00 Mil. Overall, Seaport Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Seaport Therapeutics' Current Deferred Taxes Liabilities compare to SVRA and DRTS?
Seaport Therapeutics' Current Deferred Taxes Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Biotechnology company?
A good Current Deferred Taxes Liabilities depends on the Biotechnology industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Seaport Therapeutics and its competitors. Seaport Therapeutics's current Current Deferred Taxes Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seaport Therapeutics stock overvalued right now?
Seaport Therapeutics (SPTX) has a current Current Deferred Taxes Liabilities of $0.00 Mil. The current Current Deferred Taxes Liabilities is $0.00 Mil. Seaport Therapeutics' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For Seaport Therapeutics (SPTX), the current Current Deferred Taxes Liabilities is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seaport Therapeutics Business Description

Address 101 Seaport Boulevard, Floor 12, Boston, MA, USA, 02210
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
11GF Score

Get the complete analysis for SPTX

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.04
Price